^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ATM mutation

    i
    Other names: ATM, ATA, ATC, ATD, ATDC, TEL1, TELO1, ATM serine/threonine kinase
    Entrez ID:
    472
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) (DDRiver Solid Tumours 301) (NCT04170153)
    Phase 1
    EMD Serono Research & Development Institute, Inc.
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/20/2019
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    ARID1A • ATRX
    |
    ATM mutation • ARID1A mutation
    |
    Zejula (niraparib) • tuvusertib (M1774)
    Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (NCT05941520)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/23/2024
    Primary completion :
    08/23/2027
    Completion :
    09/01/2028
    TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2
    |
    TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    tamoxifen • acolbifene
    Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors (NCT05687136)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/07/2024
    Primary completion :
    08/31/2026
    Completion :
    08/31/2026
    ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18
    |
    ATM mutation • ARID1A mutation
    |
    peposertib (M3814) • tuvusertib (M1774)
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/06/2023
    Primary completion :
    08/01/2026
    Completion :
    09/01/2026
    BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCI-2018-01648) (NCT03682289)
    Phase 2
    Rahul Aggarwal
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/17/2019
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    MSI • ATM • ARID1A • UGT1A1
    |
    ATM mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM) (NCT05222971)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2022
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    Niraparib in Tumors Metastatic to the CNS (NCT04992013)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    12/12/2024
    Initiation :
    04/05/2022
    Primary completion :
    12/01/2025
    Completion :
    06/01/2027
    BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3
    |
    HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Zejula (niraparib)
    Niraparib in Patients With Pancreatic Cancer (NCT03601923)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    10/22/2024
    Initiation :
    08/22/2018
    Primary completion :
    09/30/2025
    Completion :
    02/28/2026
    BRCA1 • BRCA2 • ATM • CHEK2
    |
    ATM mutation • PALB2 mutation • CHEK2 mutation
    |
    Zejula (niraparib)
    Olaparib in Treating Patients With Stage IV Pancreatic Cancer (NCT02677038)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/01/2024
    Initiation :
    11/11/2016
    Primary completion :
    07/18/2022
    Completion :
    07/18/2022
    BRCA1 • ATM • HRD • BRCA • RAD51
    |
    HRD • ATM mutation • BRCA mutation
    |
    Lynparza (olaparib)
    A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (Keynote MK-3475-B66) (NCT03611868)
    Phase 1/2
    Ascentage Pharma Group Inc.
    Recruiting
    Last update posted :
    07/19/2024
    Initiation :
    08/29/2018
    Primary completion :
    12/30/2024
    Completion :
    03/30/2025
    PD-L1
    |
    ATM mutation • TP53 wild-type
    |
    Keytruda (pembrolizumab) • alrizomadlin (APG-115)
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)